Skip to content

US · PAVM · MEDICAL - DEVICES

PAVmed Inc. (PAVM) intrinsic value and stock valuation

$1.14as of 2026-11-21 · Mkt cap 32.17M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PAVmed Inc. DCF and intrinsic value

InvestorsCraft values PAVM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PAVM’s statements →

PAVmed Inc. Graham Number

Graham Number: $21.13d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices New York City, NY 10165 pavmed.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$70K
20142025
Net income
$400K
20142025
Free cash flow
-$-5.21B
20142025
Total equity
$22.3M
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$70K$3M$2.45M$380K$500K
Operating income-$-21.81M-$-44.49M-$-68.8M-$-91.09M-$-54.39M
Net income$400K$39.8M-$-64.17M-$-88.98M-$-50.35M
EPSd$597K$18.3M-$-267.38M-$-444.9M-$-296.18M
Operating cash flow-$-5.21B-$-33.55M-$-52.04M-$-70.98M-$-40.59M
Capital expenditure-$-30K-$-60K-$-240K-$-1.54M-$-1.47M
Free cash flow-$-5.21B-$-33.61M-$-52.28M-$-72.53M-$-42.06M
Total assets$38.8M$30.7M$33.1M$54M$87M
Total debt$13.4M$31.9M$48.7M$36.6M$0.00
Net debt$11.8M$30.7M$29.1M-$-3.11M-$-77.26M
Total equity$22.3M-$-7.03M-$-24.02M$10.9M$79.4M
Cash and short-term investments$1.54M$1.19M$19.6M$42.8M$79.3M
Income statement
20252024202320222021
Revenue$70K$3M$2.45M$380K$500K
Cost of revenue$320K$6.04M$6.42M$3.61M$580K
Gross profit-$-250K-$-3.04M-$-3.97M-$-3.24M-$-90K
Research and development expenses$4.49B$5.93M$14.3M$25.3M$19.9M
Selling, general and administrative expenses$17.2B$36.2M$48.5M$60.7M$34.3M
Other expenses-$-21.64B-$-640K$2.02M$1.78M$150K
Operating expenses$21.6M$41.4M$64.8M$87.9M$54.3M
Cost and expenses$21.9M$47.5M$71.3M$91.5M$54.9M
Interest income$30K$250K$510K$170K$0.00
Interest expense$20K$40K$590K$1.28M$0.00
Depreciation and amortization$100K$1.2M$2.93M$2.46M$230K
Ebitda-$-2.34M$29.7M-$-75.74M-$-99.5M-$-55.9M
Operating income-$-21.81M-$-44.49M-$-68.8M-$-91.09M-$-54.39M
Total other income/expenses, net$19.3M$72.9M-$-10.47M-$-12.15M-$-1.73M
Income before tax-$-2.47M$28.4M-$-79.26M-$-103.24M-$-56.13M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$400K$39.8M-$-64.17M-$-88.98M-$-50.35M
Weighted average shares outstanding$670K$320K$240K$200K$170K
Weighted average diluted shares outstanding$670K$2.18M$240K$200K$170K
Balance sheet
20252024202320222021
Cash and short-term investments$1.54M$1.19M$19.6M$42.8M$79.3M
Net receivables$10K$20K$60K$20K$200K
Inventory$240K$270K$540K$260K$530K
Total current assets$2.56M$2.16M$24.5M$43.9M$82.6M
Property, plant and equipment, net$2.08M$2.65M$6.05M$5.49M$1.58M
Goodwill and intangible assets$0.00$0.00$1.42M$3.44M$2.03M
Long-term investments$34.1M$25.6M$0.00$0.00$0.00
Total non-current assets$36.3M$28.5M$8.62M$10.1M$4.34M
Total assets$38.8M$30.7M$33.1M$54M$87M
Accounts payable$680K$660K$1.79M$2.7M$3.3M
Short-term debt$11.7M$29.6M$45.8M$34.8M$0.00
Deferred revenue$0.00$656.3M$0.00$0.00$0.00
Total current liabilities$14.8M$35.5M$54.2M$41.2M$7.56M
Long-term debt$1.68M$2.25M$2.96M$1.85M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.68M$2.25M$2.96M$1.85M$0.00
Capital lease obligations$2.25M$2.76M$4.53M$2.99M$0.00
Total liabilities$16.5M$37.7M$57.1M$43.1M$7.56M
Common stock$0.00$10K$10K$10K$90K
Retained earnings-$-258.73M-$-254.97M-$-294.43M-$-228.17M-$-138.91M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$22.3M-$-7.03M-$-24.02M$10.9M$79.4M
Total investments$34.1M$25.6M$0.00$3M$1.99M
Total debt$13.4M$31.9M$48.7M$36.6M$0.00
Net debt$11.8M$30.7M$29.1M-$-3.11M-$-77.26M
Cash flow statement
20252024202320222021
Net income-$-2.47B$28.4M-$-79.26M-$-103.24M-$-56.13M
Depreciation and amortization$105M$1.2M$2.93M$2.46M$230K
Stock-based compensation$1.71B$6.45M$11.1M$19.5M$15M
Change in working capital$100K$510K$1.59M-$-720K-$-1.57M
Accounts receivable$0.00$40K-$-40K$180K-$-200K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$20K-$-60K-$-920K-$-740K$170K
Net cash provided by operating activities-$-5.21B-$-33.55M-$-52.04M-$-70.98M-$-40.59M
Investments in property, plant and equipment-$-30K-$-60K-$-240K-$-1.54M-$-1.47M
Acquisitions, net$0.00-$-16.48M$0.00-$-3.2M-$-2.25M
Net cash used for investing activities-$-31M-$-16.18M$760K-$-4.74M-$-3.72M
Common stock issued$5.7M$1.6M$1.82M$1.89M$117M
Common stock repurchased$0.00$0.00$0.00-$-370K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$5.59B$31.3M$31.2M$38.2M$104.3M
Net change in cash$353M-$-18.45M-$-20.11M-$-37.51M$60M
Cash at end of period$1.54B$1.19M$19.6M$39.7M$77.3M
Operating cash flow-$-5.21B-$-33.55M-$-52.04M-$-70.98M-$-40.59M
Capital expenditure-$-30K-$-60K-$-240K-$-1.54M-$-1.47M
Free cash flow-$-5.21B-$-33.61M-$-52.28M-$-72.53M-$-42.06M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PAVmed Inc.

        PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.

        CEO
        Lishan Aklog
        Employees
        41
        Beta
        0.55

        Explore

        Frequently asked questions

        What is the intrinsic value of PAVmed Inc. (PAVM)?

        InvestorsCraft does not currently publish an intrinsic value for PAVM. How the IC value is calculated.

        Is PAVM undervalued?

        InvestorsCraft does not publish an undervaluation signal for PAVM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.